

EPTRI in the **ESFRI** landmark

Giovanni Migliaccio - CVBF

EPTRI stakeholder meeting – July 09, 2020




ESFRI Roadmap 2021

The Roadmap 2021 has been launched on 25 Sept, 2019, with deadline 9 September, 2020.

With the Roadmap 2021 ESFRI will update the strategy on European RIs aimed at strengthening the competitiveness, value, excellence and impact of EU research.

The integration with the landmark RIs is required.







EPTRI process towards ESFRI

CHECK READ FILL **GUIDE & QUESTIONNAIRE ELIGIBILITY CRITERIA** ONLINE QUESTIONNAIRE Read carefully the Check national Prepare online Roadmap Guide procedure and proposal deadline to fulfill 2021 and the Questionnaire the Eligibility Criteria SEPTEMBER 2020 2 3 SEPTEMBER NATIONAL JANUARY 2019 DEADLINES 2020 INTERACTION CHECK FINALISATION MINIMAL KEY WITH DOCUMENTS **PROOF** MOS ESFRI DELEGATION REQUIREMENTS SUBMISSION Guide - EoS Interact with the Check - EoC Questionnaire LEAD ESFRI compliance with MoU Delegation or MKRs for the available at Preparation **EIROforum** www.esfri.eu Member Phase







ESFRI landmarks

The ESFRI Landmarks are RIs that were implemented, or reached an advanced Implementation Phase, under the previous Roadmap and that represent major elements of competitiveness of the ERA.

The Landmarks RI can be already delivering science services and granting user access, or can be in advanced stage of construction with a clear schedule for the start of the Operation Phase.





EPTRI integration with ESFRI landmarks

In designing EPTRI, the relationships with other existing ESFRI RIs have been carefully considered.

Eight biomedical landmark RIs have been identified as relevant with respect to some objectives of EPTRI





















EPTRI model of interaction

Survey of Landmarks scope and services

Common Services and shared expertise

Focus of unique areas of expertise and services





Survey of the existing Biomedical RIs

A survey has been performed among the existing RIs, including questions related to the available services in the following areas:

 target identification, imaging, animal/in vitro models, pharmacology assays, biomarkers and biobanks, product development, developmental biology and epidemiology.

The responders were asked whether they received requests related to paediatric research and which other services relevant to paediatric drug development can be provided.





Landmarks survey results

The conclusions of this survey have been:

EUROPEAN PAEDIATRIC TRANSLATIONAL RESEARCH INFRASTRUCTUR

- Most of the services in the drug development field are provided by existing RIs, often by more than one RI.
- As generalist, the Landmark RIs did not track paediatric specific requests of service.
- There are relevant research activities and services within the EPTRI community that are not provided by any of the existing RIs.
- Technologies that can be offered to paediatric users by creating common activities with EPTRI have been



Action taken

These results have been considered for the EPTRI CDR as follows:

- Limit the number of services to be provided within EPTRI in order to avoid duplications with existing services.
- Create collaborative activities for technologies and services of common interest that need to be adapted from the general to the paediatric setting.

A plan of work is described in Deliverable 4.5 - Plan for interaction, integration and collaboration with the other Research Infrastructures.

EUROPEAN PAEDIATRIC TRANSLATIONAL RESEARCH INFRASTRUCTURE

Common Services

Access through EPTRI single access point (SAP) to

- bilateral or multilateral collaboration for most required or frequently used services or combination of services
- access to multiple infrastructures if joint services are identified


Or\and

✓ common development of additional services.





Collaboration options







Action planned



Networking activities

To foster a culture of cooperation between research infrastructures, scientific communities, industries and other stakeholders as appropriate, and to help develop a more efficient and attractive European Research Area





Trans-national access or virtual access activities

To support scientific communities in their access to the identified key research infrastructures



Joint research activities

To improve, in quality and/or quantity, the integrated services provided at European level by the infrastructures









